PV Section 3 3.1: management of adverse events reports from spontaneous reporting 3.1.1: Single case Processing Activities: SOP 202 defines the responsibilities of LSU For…

Slide 1The PROTECT project Olaf Klungel, PharmD, PhD Division of Pharmacoepidemiology & Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht…

Slide 1September, 2005 HIMSS Interoperability Showcase New Directions in Life Sciences Theater Presentation Supporting Physician Reporting of Adverse Reactions and Public…

Slide 1Improving Spontaneous Reporting: A new business model Incorporating postmarket medical product safety data collection into the clinical practice workflow at the point-of-care…

Slide 1Advanced Therapy Regulation Hearing, Brussels May 11, 2006 Dr.Andreas Reimann CEO, Mukoviszidose e.V. (German Cystic Fibrosis Association) Vice-Chairman, ACHSE e.V.…

Slide 11 WHO Programme for International Drug Monitoring : ensuring the safety of medicines Dr Mary Couper & Dr Shanthi Pal Quality Assurance and Safety: Medicines Department…

1.Introduction to Post-marketing Drug Safety Surveillance:Pharmacovigilance in FDA/CDER CDR Selena Ready, PharmD, CGP Safety Evaluator Division of Pharmacovigilance Office…

1. Updates on the BioSense Program Redesign2011 Public Health Preparedness SummitSession WS-16—Location International 10Tuesday, February 22, 2011 1:30 PM- 5:30 PMAtlanta,…

1. Novel Approaches in Public Health SurveillanceBioSense Program Redesign, Meaningful Use, and Syndromic SurveillanceInternational Meeting on Emerging Diseases and Surveillance…

1. ASTER One Year Later A New Business Model for Postmarketing Reporting 2. Session Participants • Michael Ibara (Pfizer) – Setting the stage – ASTER• Landen Bain…